

Alexa B Kimball

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2109916/publications.pdf>

Version: 2024-02-01

278
papers

18,609
citations

16451

64
h-index

14208

128
g-index

283
all docs

283
docs citations

283
times ranked

11381
citing authors

#	ARTICLE	IF	CITATIONS
1	Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations. Journal of the American Academy of Dermatology, 2022, 86, 1092-1101.	1.2	77
2	Hidradenitis Suppurativa Epidemiology. , 2022, , 10-17.		2
3	Clinical Evaluation. , 2022, , 62-68.		0
4	Impact of childhood atopic dermatitis on life decisions for caregivers and families. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	5
5	The Yin and Yang of Skin Microbiota in “Swimmer Acne” Experimental Dermatology, 2022, , .	2.9	4
6	Treatment Outcomes Associated With Dupilumab Use in Patients With Atopic Dermatitis. JAMA Dermatology, 2022, 158, 142.	4.1	8
7	Aging-Associated Changes in the Adult Human Skin Microbiome and the Host Factors that Affect Skin Microbiome Composition. Journal of Investigative Dermatology, 2022, 142, 1934-1946.e21.	0.7	29
8	Unmet clinical needs and burden of disease in hidradenitis suppurativa: real-world experience from EU5 and US. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1597-1605.	2.4	15
9	Advances in biologic and small molecule therapies for hidradenitis suppurativa. Expert Opinion on Pharmacotherapy, 2022, 23, 959-978.	1.8	4
10	Dermatologic inflammatory conditions require high loading and maintenance doses of biologic therapy. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	0
11	IL-17A is a pertinent therapeutic target for moderate-to-severe hidradenitis suppurativa: Combined results from a pre-clinical and phase proof-of-concept study. Experimental Dermatology, 2022, 31, 1522-1532.	2.9	18
12	Psoriasis: Knowledge, attitudes and perceptions among primary care providers. Journal of the American Academy of Dermatology, 2021, 84, 1421-1423.	1.2	3
13	Psoriasis severity: commonly used clinical thresholds may not adequately convey patient impact. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 417-421.	2.4	11
14	Impact of Endometriosis on Life-Course Potential: A Narrative Review. International Journal of General Medicine, 2021, Volume 14, 9-25.	1.8	75
15	Plastic Surgical Management of Hidradenitis Suppurativa. Plastic and Reconstructive Surgery, 2021, 147, 479-491.	1.4	10
16	Pregnancy Outcomes in Women With Moderate-to-Severe Psoriasis From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). JAMA Dermatology, 2021, 157, 301.	4.1	21
17	A visit guide for hidradenitis suppurativa—Managing a complex disease in a busy clinic. Journal of the American Academy of Dermatology, 2021, 84, e155-e160.	1.2	4
18	Quantifying Itch: Measurement on the Way to Management. , 2021, 107, 167-168.		0

#	ARTICLE	IF	CITATIONS
19	A safety review of biologic therapies for the management of hidradenitis suppurativa and unmet needs. Expert Opinion on Drug Safety, 2021, 20, 1147-1161.	2.4	6
20	Telehealth Use by Age and Race at a Single Academic Medical Center During the COVID-19 Pandemic: Retrospective Cohort Study. Journal of Medical Internet Research, 2021, 23, e23905.	4.3	28
21	Response to Letter to the Editor entitled: Rethinking biologic and pregnancy research: The importance of assessing postpartum immunosuppression of the infant. International Journal of Women's Dermatology, 2021, 7, 510-511.	2.0	0
22	Hidradenitis suppurativa disease course during pregnancy and postpartum: a retrospective survey study. British Journal of Dermatology, 2021, 185, 1072-1074.	1.5	5
23	Transcriptomic analysis of human skin wound healing and rejuvenation following ablative fractional laser treatment. PLoS ONE, 2021, 16, e0260095.	2.5	4
24	Refining how we measure as we test: new insights using adalimumab in patients with hidradenitis suppurativa. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 2342-2342.	2.4	0
25	Effects of swimming on facial sebum in adolescents. Pediatric Dermatology, 2021, , .	0.9	0
26	Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab. British Journal of Dermatology, 2020, 182, 180-189.	1.5	22
27	Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. Journal of the American Academy of Dermatology, 2020, 82, 117-122.	1.2	120
28	Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies. British Journal of Dermatology, 2020, 182, 1359-1368.	1.5	20
29	Investigating race and gender in age at onset of hidradenitis suppurativa. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e139-e141.	2.4	9
30	Maintenance of clinical response and consistent safety profile with up to 3Âyears of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials. Journal of the American Academy of Dermatology, 2020, 82, 936-945.	1.2	71
31	Baseline patientâ€reported outcomes from <scp>UNITE</scp>: an observational, international, multicentre registry to evaluate hidradenitis suppurativa in clinical practice. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1302-1308.	2.4	11
32	Metabolic dysfunction in human skin: Restoration of mitochondrial integrity and metabolic output by nicotinamide (niacinamide) in primary dermal fibroblasts from older aged donors. Aging Cell, 2020, 19, e13248.	6.7	18
33	What causes hidradenitis suppurativa "15 years after. Experimental Dermatology, 2020, 29, 1154-1170.	2.9	90
34	High placebo rates in clinical trials: Is the problem scoring systems or drug efficacy?. Journal of the American Academy of Dermatology, 2020, 83, e431.	1.2	5
35	Burnout Among All Groups of Physiciansâ€Mitigation Strategies for Dermatologists. JAMA Dermatology, 2020, 156, 1049.	4.1	3
36	Hidradenitis suppurativa. Nature Reviews Disease Primers, 2020, 6, 18.	30.5	286

#	ARTICLE	IF	CITATIONS
37	Risk of COVID-19 in dermatologic patients receiving long-term immunomodulatory therapy. Journal of the American Academy of Dermatology, 2020, 83, 1215-1218.	1.2	18
38	Methotrexate shows benefit in a subset of patients with severe hidradenitis suppurativa. International Journal of Women's Dermatology, 2020, 6, 159-163.	2.0	8
39	Baseline Characteristics from UNITE: An Observational, International, Multicentre Registry to Evaluate Hidradenitis Suppurativa (Acne Inversa) in Clinical Practice. American Journal of Clinical Dermatology, 2020, 21, 579-590.	6.7	16
40	Biologic therapies for the treatment of hidradenitis suppurativa. Expert Opinion on Biological Therapy, 2020, 20, 621-633.	3.1	11
41	Publication trends in hidradenitis suppurativa from 2008 to 2018. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1885-1889.	2.4	13
42	Tofacitinib shows benefit in conjunction with other therapies in recalcitrant hidradenitis suppurativa patients. JAAD Case Reports, 2020, 6, 99-102.	0.8	39
43	Reply to: "Lack of a US Food and Drug Administration indication should not limit access to appropriate treatment". Journal of the American Academy of Dermatology, 2019, 81, e19-e20.	1.2	0
44	TNF- α inhibitors in the treatment of hidradenitis suppurativa. Therapeutic Advances in Chronic Disease, 2019, 10, 204062231985164.	2.5	33
45	Biologic Treatment for Hidradenitis Suppurativa. American Journal of Clinical Dermatology, 2019, 20, 625-638.	6.7	21
46	North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations. Journal of the American Academy of Dermatology, 2019, 81, 91-101.	1.2	206
47	North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations. Journal of the American Academy of Dermatology, 2019, 81, 76-90.	1.2	218
48	Genetic basis for skin youthfulness. Clinics in Dermatology, 2019, 37, 312-319.	1.6	16
49	Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1098-1106.	2.4	19
50	Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials. British Journal of Dermatology, 2019, 181, 967-975.	1.5	34
51	Use of biologics in pregnancy: limitations stemming from clinical trials and registry experience. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e276-e277.	2.4	2
52	Disease burden and cost of hidradenitis suppurativa: a retrospective examination of US administrative claims data. BMJ Open, 2019, 9, e030579.	1.9	43
53	Examining the prior authorization process, patient outcomes, and the impact of a pharmacy intervention: A single-center review. Journal of the American Academy of Dermatology, 2019, 81, 1308-1318.	1.2	13
54	Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization "systematic review and recommendations from the HS ALLIANCE working group. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 19-31.	2.4	168

#	ARTICLE	IF	CITATIONS
55	Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 333-339.	2.4	50
56	Clinical Goals and Barriers to Effective Psoriasis Care. Dermatology and Therapy, 2019, 9, 5-18.	3.0	63
57	Antiandrogen therapy with spironolactone for the treatment of hidradenitis suppurativa. Journal of the American Academy of Dermatology, 2019, 80, 114-119.	1.2	54
58	Online communications among hidradenitis suppurativa patients reflect community needs. Journal of the American Academy of Dermatology, 2019, 80, 1760-1762.	1.2	12
59	Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized <scp>VOYAGE</scp> 1 and <scp>VOYAGE</scp> 2 studies. British Journal of Dermatology, 2019, 180, 1039-1049.	1.5	57
60	Hidradenitis suppurativa for the dermatologic hospitalist. Cutis, 2019, 104, 276-280.	0.3	2
61	Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized <scp>VOYAGE</scp> 1 trial. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1515-1522.	2.4	19
62	Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis. Journal of the American Academy of Dermatology, 2018, 79, 294-301.e6.	1.2	22
63	Pregnancy Outcomes After Exposure to Certolizumab Pegol. Arthritis and Rheumatology, 2018, 70, 1399-1407.	5.6	129
64	28 CHARACTERISTICS AND OUTCOMES OF PROSPECTIVELY REPORTED PREGNANCIES EXPOSED TO CERTOLIZUMAB PEGOL FROM A SAFETY DATABASE. Gastroenterology, 2018, 154, S9-S10.	1.3	0
65	Understanding patient engagement in psoriasis treatment. British Journal of Dermatology, 2018, 178, 988-989.	1.5	3
66	Pharmacoeconomics of Systemic and Biologic Therapy in Dermatology. , 2018, , 83-91.		1
67	Development and initial psychometric evaluation of patient-reported outcome questionnaires to evaluate the symptoms and impact of hidradenitis suppurativa. Journal of Dermatological Treatment, 2018, 29, 152-164.	2.2	33
68	Adverse Reactions to Biologics in Psoriasis. Current Problems in Dermatology, 2018, 53, 1-14.	0.7	20
69	Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR). Journal of the American Academy of Dermatology, 2018, 78, 70-80.	1.2	78
70	Age-induced and photoinduced changes in gene expression profiles in facial skin of Caucasian females across 6 decades of age. Journal of the American Academy of Dermatology, 2018, 78, 29-39.e7.	1.2	50
71	AB0912...Two-year efficacy and safety of guselkumab for treatment of moderate-to-severe psoriasis: phase 3 voyage 1 trial. , 2018, , .		5
72	An assessment of the relative impact of hidradenitis suppurativa, psoriasis, and obesity on quality of life. International Journal of Women's Dermatology, 2018, 4, 198-202.	2.0	12

#	ARTICLE	IF	CITATIONS
73	The Comorbidity Burden of Hidradenitis Suppurativa in the United States: A Claims Data Analysis. <i>Dermatology and Therapy</i> , 2018, 8, 557-569.	3.0	51
74	Predictions, Surprises, and the Future of the Dermatology Workforce. <i>JAMA Dermatology</i> , 2018, 154, 1253.	4.1	14
75	Achieving Hidradenitis Suppurativa Response Score is Associated with Significant Improvement in Clinical and Patient-reported Outcomes: Post Hoc Analysis of Pooled Data From PIONEER I and II. <i>Acta Dermato-Venereologica</i> , 2018, 98, 932-937.	1.3	17
76	Long-term Impact of Ixekizumab on Psoriasis Itch Severity: Results from a Phase III Clinical Trial and Long-term Extension. <i>Acta Dermato-Venereologica</i> , 2018, 98, 98-102.	1.3	21
77	Assessment of treatment-seeking behaviour in patients with psoriasis. <i>British Journal of Dermatology</i> , 2018, 179, 989-990.	1.5	2
78	Adalimumab alleviates skin pain in patients with moderate-to-severe hidradenitis suppurativa: Secondary efficacy results from the PIONEER I and PIONEER II randomized controlled trials. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 1141-1143.	1.2	21
79	Reliability of the hidradenitis suppurativa clinical response in the assessment of patients with hidradenitis suppurativa. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 2254-2256.	2.4	14
80	Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials. <i>British Journal of Dermatology</i> , 2018, 179, 615-622.	1.5	57
81	Correlation of psoriasis activity with socioeconomic status: cross-sectional analysis of patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). <i>British Journal of Dermatology</i> , 2018, 179, 984-986.	1.5	10
82	Overview and update on biologic therapy for moderate-to-severe hidradenitis suppurativa. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2018, 37, 182-189.	1.6	13
83	Current guidelines for psoriasis treatment: a work in progress. <i>Cutis</i> , 2018, 101, 10-12.	0.3	30
84	Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years. <i>Journal of Drugs in Dermatology</i> , 2018, 17, 826-832.	0.8	31
85	Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 405-417.	1.2	673
86	Prevalence and Risk of Inflammatory Bowel Disease in Patients with Hidradenitis Suppurativa. <i>Journal of Investigative Dermatology</i> , 2017, 137, 1060-1064.	0.7	68
87	Understanding the cost of dermatologic care: A survey study of dermatology providers, residents, and patients. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 609-617.	1.2	11
88	Itch intensity in moderate-to-severe plaque psoriasis versus atopic dermatitis: A meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 1198-1200.e1.	1.2	16
89	Pediatric Psoriasis Comorbidity Screening Guidelines. <i>JAMA Dermatology</i> , 2017, 153, 698.	4.1	84
90	Observations from our evaluation of bodyweight changes after initiation of a biologic therapy in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e544-e547.	2.4	2

#	ARTICLE	IF	CITATIONS
91	Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE) Tj ETQq1 1.0, 784314, rgBT / Overlock 10 Tf 50	13.7	428
92	Update on biologic safety for patients with psoriasis during pregnancy. International Journal of Women's Dermatology, 2017, 3, 21-25.	2.0	76
93	Psoriasis and latitude: Analytic approaches and future data needs. Journal of the American Academy of Dermatology, 2017, 77, e59.	1.2	2
94	Secukinumab improves scalp pain, itching, scaling and quality of life in patients with moderate-to-severe scalp psoriasis. Journal of Dermatological Treatment, 2017, 28, 716-721.	2.2	22
95	The Impact of Administrative Burden on Academic Physicians: Results of a Hospital-Wide Physician Survey. Academic Medicine, 2017, 92, 237-243.	1.6	126
96	Development and validation of the International Hidradenitis Suppurativa Severity Score System () Tj ETQq0 0 0 rgBT / Overlock 10 Tf 50	1.5	301
97	UnerwÃ¼nschte Wirkungen von Biologika bei Psoriasis. Karger Kompass Dermatologie, 2017, 5, 195-199.	0.0	1
98	Comorbidities of hidradenitis suppurativa. Seminars in Cutaneous Medicine and Surgery, 2017, 36, 55-57.	1.6	22
99	Hidradenitis suppurativa scoring systems: can we choose just one?. Cutis, 2017, 99, 156-157.	0.3	3
100	Getting under the Skin: Report from the International Psoriasis Council Workshop on the Role of Stress in Psoriasis. Frontiers in Psychology, 2016, 7, 87.	2.1	14
101	The temporal association between cutaneous Tâ€cell lymphoma and psoriasis: implications for common biologic processes. Journal of the European Academy of Dermatology and Venereology, 2016, 30, e31-e32.	2.4	10
102	Effects of <scp>TNF</scp>â€alpha antagonism in patients with metabolic syndrome and psoriasis. Journal of the European Academy of Dermatology and Venereology, 2016, 30, e152-e154.	2.4	3
103	Managing the dose escalation of biologics in an era of cost containment: the need for a rational strategy. International Journal of Women's Dermatology, 2016, 2, 151-153.	2.0	12
104	Systemic causes of hair loss. Annals of Medicine, 2016, 48, 393-402.	3.8	22
105	A novel approach to administration of peptides in women: Systemic absorption of a GnRH agonist via transvaginal ring delivery system. Journal of Controlled Release, 2016, 233, 19-28.	9.9	18
106	Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials. Journal of the American Academy of Dermatology, 2016, 75, 1156-1161.	1.2	39
107	Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. New England Journal of Medicine, 2016, 375, 422-434.	27.0	530
108	Psychometric properties of the Itch Numeric Rating Scale in patients with moderateâ€toâ€severe plaque psoriasis. British Journal of Dermatology, 2016, 175, 157-162.	1.5	81

#	ARTICLE	IF	CITATIONS
109	HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 989-994.	2.4	137
110	A Closer Inspection of the Number Needed to Biopsy—Reply. JAMA Dermatology, 2016, 152, 953.	4.1	0
111	Acne Knowledge of Hispanic Parents of Teenagers with Mild to Moderate Acne. Pediatric Dermatology, 2016, 33, e292-e293.	0.9	4
112	Targeted Reminder Phone Calls to Patients at High Risk of No-Show for Primary Care Appointment: A Randomized Trial. Journal of General Internal Medicine, 2016, 31, 1460-1466.	2.6	36
113	Survey on Clinician Perceptions and Practices Regarding Goals of Care Conversations. Journal of Palliative Medicine, 2016, 19, 1215-1217.	1.1	8
114	Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis. Drug Safety, 2016, 39, 755-762.	3.2	112
115	The spectrum of nephrocutaneous diseases and associations. Journal of the American Academy of Dermatology, 2016, 74, 231-244.	1.2	5
116	The spectrum of nephrocutaneous diseases and associations. Journal of the American Academy of Dermatology, 2016, 74, 247-270.	1.2	5
117	Brodalumab and suicidal ideation in the context of a recent economic crisis in the United States. Journal of the American Academy of Dermatology, 2016, 74, 190-192.	1.2	36
118	Performing research in pregnancy: Challenges and perspectives. Clinics in Dermatology, 2016, 34, 410-415.	1.6	5
119	Should We Leave the Skin Biopsies to the Dermatologists?. JAMA Dermatology, 2016, 152, 371.	4.1	8
120	Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and) Tj ETQq0 0 0 rgBT /Owlock 103Tf 50 297	4.2	10
121	Longer-term impact of cardiology e-consults. American Heart Journal, 2016, 173, 86-93.	2.7	49
122	Teachable Action for Leaders Committed to Improving Physician Work Life: Continuing Education. Mayo Clinic Proceedings, 2015, 90, 1455-1456.	3.0	0
123	Cohort study of malignancies and hospitalized infectious events in treated and untreated patients with psoriasis and a general population in the United States. British Journal of Dermatology, 2015, 173, 1183-1190.	1.5	40
124	The Utility of Laser Thermometry in Grading Plaque Psoriasis. Journal of Psoriasis and Psoriatic Arthritis, 2015, 1, 15-17.	0.7	0
125	Using the Physician Global Assessment in a Clinical Setting to Measure and Track Patient Outcomes. JAMA Dermatology, 2015, 151, 375.	4.1	59
126	OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results. Journal of the American Academy of Dermatology, 2015, 72, 115-122.	1.2	62

#	ARTICLE	IF	CITATIONS
127	Delivering value in dermatology: Insights from skin cancer detection in routine clinical visits. Journal of the American Academy of Dermatology, 2015, 72, 310-313.	1.2	9
128	Psoriasis patients'™ willingness to accept side-effect risks for improved treatment efficacy. Journal of Dermatological Treatment, 2015, 26, 507-513.	2.2	22
129	Patient navigation based on predictive modeling decreases no-show rates in cancer care. Cancer, 2015, 121, 1662-1670.	4.1	43
130	Expanding Scope of Dermatologic Mid-Level Practitioners Includes Prescription of Complex Medication. JAMA Dermatology, 2015, 151, 106.	4.1	2
131	Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. New England Journal of Medicine, 2015, 373, 1318-1328.	27.0	656
132	Psoriasis and Cardiovascular Disease. Medical Clinics of North America, 2015, 99, 1227-1242.	2.5	26
133	Hidradenitis suppurativa: Epidemiology and scope of the problem. Journal of the American Academy of Dermatology, 2015, 73, S4-S7.	1.2	173
134	Systemic associations of hidradenitis suppurativa. Journal of the American Academy of Dermatology, 2015, 73, S27-S35.	1.2	115
135	Seasonal variation of acne and psoriasis: A 3-year study using the Physician Global Assessment severity scale. Journal of the American Academy of Dermatology, 2015, 73, 523-525.	1.2	32
136	Psoriasis and herpes simplex virus are highly stigmatizing compared with other common dermatologic conditions: A survey-based study. Journal of the American Academy of Dermatology, 2015, 73, 525-526.	1.2	19
137	Chronic pain management in dermatology. Journal of the American Academy of Dermatology, 2015, 73, 575-582.	1.2	12
138	Chronic pain management in dermatology. Journal of the American Academy of Dermatology, 2015, 73, 563-573.	1.2	17
139	A measure of chronic quality of life predicts socioeconomic and medical outcomes in psoriasis patients. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 249-254.	2.4	14
140	Itching is a significant problem and a mediator between disease severity and quality of life for patients with psoriasis: results from a randomized controlled trial. British Journal of Dermatology, 2014, 171, 1215-1219.	1.5	53
141	Incidence rates of malignancies and hospitalized infectious events in patients with psoriasis with or without treatment and a general population in the U.S.A.: 2005-09. British Journal of Dermatology, 2014, 170, 366-373.	1.5	48
142	Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR). British Journal of Dermatology, 2014, 171, 137-147.	1.5	104
143	The validity of the diagnostic code for hidradenitis suppurativa in an electronic database. British Journal of Dermatology, 2014, 171, 338-342.	1.5	37
144	Hidradenitis Suppurativa. JAMA Dermatology, 2014, 150, 1263.	4.1	9

#	ARTICLE	IF	CITATIONS
145	Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 333-337.	2.4	217
146	Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: A chart-verified case-control analysis. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 1144-1150.	1.2	235
147	Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory. <i>British Journal of Dermatology</i> , 2014, 170, 705-715.	1.5	48
148	Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment. <i>British Journal of Dermatology</i> , 2014, 171, 1434-1442.	1.5	156
149	Dermatology urgent care: Enlisting help from primary care in triage decisions. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 838-839.	1.2	3
150	Accumulating Evidence for the Association and Shared Pathogenic Mechanisms Between Psoriasis and Cardiovascular-related Comorbidities. <i>American Journal of Medicine</i> , 2014, 127, 1148-1153.	1.5	59
151	The relative impact of psoriasis and obesity on socioeconomic and medical outcomes in psoriasis patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 216-221.	2.4	15
152	An evaluation of educational debt levels in dermatology residents and effects on career choices. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 1141-1142.	1.2	2
153	Meta-analysis comparing efficacy of antibiotics versus oral contraceptives in acne vulgaris. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 450-459.	1.2	52
154	Real-time location systems, normative messaging and modifying clinician behavior: a pilot study. <i>Health Systems</i> , 2014, 3, 165-172.	1.2	3
155	Management of Hidradenitis Suppurativa Wounds with an Internal Vacuum-Assisted Closure Device. <i>Plastic and Reconstructive Surgery</i> , 2014, 133, 370e-377e.	1.4	36
156	Dermatologic workforce on the Texas border: using burden on primary care as an outcome measure. <i>International Journal of Dermatology</i> , 2013, 52, 506-507.	1.0	1
157	Psoriasis prevalence among the 2009 AAD National Melanoma/Skin Cancer Screening Program participants. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 680-685.	2.4	34
158	Psoriasis Epidemiology: The Interplay of Genes and the Environment. <i>Journal of Investigative Dermatology</i> , 2013, 133, 287-289.	0.7	84
159	Counterpoint: Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, 818-819.	1.2	25
160	OBSERVE-5 interim analysis: An observational postmarketing safety registry of etanercept for the treatment of psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2013, 68, 756-764.	1.2	31
161	Prevalence of Skin Disorders in Patients Seeking Health Care. <i>Mayo Clinic Proceedings</i> , 2013, 88, 776.	3.0	1
162	Self-Reported Help-Seeking Behaviors and Treatment Choices of Adolescents Regarding Acne. <i>Pediatric Dermatology</i> , 2013, 30, 36-41.	0.9	24

#	ARTICLE	IF	CITATIONS
163	Topical Chemotherapy in Cutaneous T-cell Lymphoma. JAMA Dermatology, 2013, 149, 25.	4.1	147
164	Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 1535-1545.	2.4	166
165	Cutaneous effects of BRAF inhibitor therapy: a case series. Annals of Oncology, 2013, 24, 530-537.	1.2	73
166	Cumulative Life Course Impairment: Evidence for Psoriasis. Current Problems in Dermatology, 2013, 44, 82-90.	0.7	38
167	Early development and qualitative evidence of content validity for the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure of psoriasis symptom severity. Journal of Dermatological Treatment, 2013, 24, 255-260.	2.2	35
168	Validation of a Screening Instrument for Nephrogenic Systemic Fibrosis. Arthritis Care and Research, 2013, 65, 637-642.	3.4	2
169	Specializing in Accountability. Academic Medicine, 2013, 88, 1900-1903.	1.6	6
170	Treatment of Moderate to Severe Hidradenitis Suppurativa. Annals of Internal Medicine, 2013, 159, 72.	3.9	1
171	Weight loss in obese patients with psoriasis can be successfully achieved during a course of phototherapy. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 1582-1584.	2.4	15
172	Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa. Annals of Internal Medicine, 2012, 157, 846.	3.9	349
173	The Impact of Psoriasis on Pregnancy Outcomes. Journal of Investigative Dermatology, 2012, 132, 85-91.	0.7	66
174	Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): Why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. Journal of the American Academy of Dermatology, 2012, 66, 369-375.	1.2	158
175	Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis. Journal of the American Academy of Dermatology, 2012, 67, 76-85.	1.2	99
176	Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials. Journal of the American Academy of Dermatology, 2012, 66, 742-751.	1.2	124
177	Teaching empathy to undergraduate medical students using a temporary tattoo simulating psoriasis. Journal of the American Academy of Dermatology, 2012, 67, 93-99.	1.2	11
178	Psoriasis and cardiovascular disease: another contribution in the hierarchy of evidence. British Journal of Dermatology, 2012, 167, 1198-1199.	1.5	2
179	Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. British Journal of Dermatology, 2012, 166, 861-872.	1.5	121
180	Increased diagnosis of thin superficial spreading melanomas: A 20-year study. Journal of the American Academy of Dermatology, 2012, 67, 387-394.	1.2	68

#	ARTICLE	IF	CITATIONS
181	Risks of developing psychiatric disorders in pediatric patients with psoriasis. Journal of the American Academy of Dermatology, 2012, 67, 651-657.e2.	1.2	149
182	Skin carotenoid levels are not associated with risk of nonmelanoma skin cancer: Response to "Supplement use and the risk of cutaneous squamous cell carcinoma". Journal of the American Academy of Dermatology, 2012, 67, 1071-1072.	1.2	0
183	Acne Vulgaris in Women: Prevalence Across the Life Span. Journal of Women's Health, 2012, 21, 223-230.	3.3	86
184	Association of systemic psoriasis therapies and incidence of myocardial infarction: reply from authors. British Journal of Dermatology, 2012, 166, 233-233.	1.5	1
185	A new era in skin care: the omics revolution. British Journal of Dermatology, 2012, 166, iii-iv.	1.5	1
186	Beyond the blot: cutting edge tools for genomics, proteomics and metabolomics analyses and previous successes. British Journal of Dermatology, 2012, 166, 1-8.	1.5	24
187	Efficacy and Safety of Adalimumab among Patients with Moderate to Severe Psoriasis with Co-Morbidities. American Journal of Clinical Dermatology, 2011, 12, 51-62.	6.7	52
188	Latitude and psoriasis prevalence. Journal of the American Academy of Dermatology, 2011, 65, 870-873.	1.2	57
189	Efficacy and safety of ABT-874, a monoclonal anti-interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trial. Journal of the American Academy of Dermatology, 2011, 64, 263-274.	1.2	30
190	Meta-analysis of randomized controlled trials using 5% benzoyl peroxide and clindamycin versus 2.5% benzoyl peroxide and clindamycin topical treatments in acne. Journal of the American Academy of Dermatology, 2011, 65, e117-e119.	1.2	21
191	The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study. British Journal of Dermatology, 2011, 165, 1066-1073.	1.5	103
192	Economic burden of comorbidities in patients with psoriasis is substantial. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 157-163.	2.4	100
193	Skin carotenoid levels in adult patients with psoriasis. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 945-949.	2.4	22
194	Comparison of the epidemiology of acne vulgaris among Caucasian, Asian, Continental Indian and African American women. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 1054-1060.	2.4	119
195	Re. major life-changing decisions and cumulative life course impairment. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 246-246.	2.4	6
196	Association Between Biologic Therapies for Chronic Plaque Psoriasis and Cardiovascular Events. JAMA - Journal of the American Medical Association, 2011, 306, 864-71.	7.4	259
197	A Cost-effectiveness Comparison of Liquor Carbonis Distillate Solution and Calcipotriol Cream in the Treatment of Moderate Chronic Plaque Psoriasis. Archives of Dermatology, 2010, 146, 919-22.	1.4	3
198	Self-Reported Acne Severity, Treatment, and Belief Patterns across Multiple Racial and Ethnic Groups in Adolescent Students. Pediatric Dermatology, 2010, 27, 446-452.	0.9	40

#	ARTICLE	IF	CITATIONS
199	Psoriasis: is the impairment to a patient's life cumulative?. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 989-1004.	2.4	180
200	Correspondence: Assessing dermatology board examination competence using questions distribution: a 12-year Brazilian experience. International Journal of Dermatology, 2010, 49, 1080-1082.	1.0	1
201	Reduction in the appearance of facial hyperpigmentation after use of moisturizers with a combination of topical niacinamide and N-acetyl glucosamine: results of a randomized, double-blind, vehicle-controlled trial. British Journal of Dermatology, 2010, 162, 435-441.	1.5	55
202	OBSERVE-5, an Observational Post-Marketing Safety Surveillance Registry of Etanercept for the Treatment of Psoriasis: A Model for Studying New Psoriasis Therapies. Psoriasis Forum, 2010, 16a, 3-7.	0.1	4
203	Meta-analysis comparing efficacy of benzoyl peroxide, clindamycin, benzoyl peroxide with salicylic acid, and combination benzoyl peroxide/clindamycin in acne. Journal of the American Academy of Dermatology, 2010, 63, 52-62.	1.2	60
204	Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial. Journal of the American Academy of Dermatology, 2010, 63, 457-465.	1.2	180
205	Health Disparities Among Different Ethnic and Racial Middle and High School Students in Sun Exposure Beliefs and Knowledge. Journal of Adolescent Health, 2010, 47, 106-109.	2.5	26
206	Efficacy and Tolerability of a Cosmetically Acceptable Coal Tar Solution in the Treatment of Moderate Plaque Psoriasis. American Journal of Clinical Dermatology, 2010, 11, 1.	6.7	18
207	Melanoma in Hong Kong between 1983 and 2002: a decreasing trend in incidence observed in a complex socio-political and economic setting. Melanoma Research, 2010, 20, 427-430.	1.2	9
208	Targeting IL-23: Insights into the pathogenesis and the treatment of psoriasis. Indian Journal of Dermatology, 2010, 55, 171.	0.3	13
209	Text-Message Reminders to Improve Sunscreen Use. Archives of Dermatology, 2009, 145, 1230-6.	1.4	213
210	Briakinumab. Expert Opinion on Biological Therapy, 2009, 9, 1107-1113.	3.1	35
211	Socioeconomic disability in psoriasis. British Journal of Dermatology, 2009, 161, 1410-1412.	1.5	12
212	Long-term safety of biologics in dermatology. Dermatologic Therapy, 2009, 22, 2-21.	1.7	13
213	The burden of autoimmune disease: A comparison of prevalence ratios in patients with psoriatic arthritis and psoriasis. Journal of the American Academy of Dermatology, 2009, 61, 405-410.	1.2	99
214	Patient preferences for dermatology visits. Journal of the American Academy of Dermatology, 2009, 61, 1083-1084.	1.2	1
215	Pregnancy outcomes in psoriasis: Why do we know so little?. Journal of the American Academy of Dermatology, 2009, 61, e5-e8.	1.2	33
216	New antifungal therapies for the treatment of onychomycosis. Expert Opinion on Investigational Drugs, 2009, 18, 727-734.	4.1	42

#	ARTICLE	IF	CITATIONS
217	Survey Research in Dermatology: Guidelines for Success. <i>Dermatologic Clinics</i> , 2009, 27, 121-131.	1.7	9
218	Impact of Film ("My Skin's on Fire: Living With Psoriasis") on Medical Student Education in Dermatology. <i>Journal of the Dermatology Nurses' Association</i> , 2009, 1, 190-194.	0.1	0
219	Skin and Anti-Aging Research Update: Proceedings from the 2007 World Congress of Dermatology. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2008, 13, 1.	0.8	0
220	Skin Differences, Needs, and Disorders across Global Populations. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2008, 13, 2-5.	0.8	11
221	Patient-Reported Outcomes and Health-Care Resource Utilization in Patients with Psoriasis Treated with Etanercept: Continuous versus Interrupted Treatment. <i>Value in Health</i> , 2008, 11, 400-407.	0.3	56
222	A Single-Blinded, Randomized Pilot Study to Evaluate the Effect of Exercise-Induced Sweat on Truncal Acne. <i>Pediatric Dermatology</i> , 2008, 25, 126-128.	0.9	12
223	Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 106-115.	1.2	796
224	Who else is providing care in dermatology practices? Trends in the use of nonphysician clinicians. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 211-216.	1.2	84
225	Fate of manuscripts declined by the <i>Journal of the American Academy of Dermatology</i> . <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 632-635.	1.2	34
226	Acne and oral contraceptives: Update on women's health screening guidelines. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 781-786.	1.2	21
227	National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 1031-1042.	1.2	383
228	Rethinking eligibility creep. <i>Journal of the American Academy of Dermatology</i> , 2008, 59, 165-167.	1.2	2
229	The US dermatology workforce: A specialty remains in shortage. <i>Journal of the American Academy of Dermatology</i> , 2008, 59, 741-745.	1.2	222
230	Cutaneous manifestations of thyroid disease. <i>Clinics in Dermatology</i> , 2008, 26, 283-287.	1.6	57
231	Future perspectives/quo vadis psoriasis treatment? Immunology, pharmacogenomics, and epidemiology. <i>Clinics in Dermatology</i> , 2008, 26, 554-561.	1.6	6
232	Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). <i>Lancet, The</i> , 2008, 371, 1665-1674.	13.7	1,572
233	Safety and Efficacy of ABT-874, a Fully Human Interleukin 12/23 Monoclonal Antibody, in the Treatment of Moderate to Severe Chronic Plaque Psoriasis. <i>Archives of Dermatology</i> , 2008, 144, 200.	1.4	207
234	Quality of Life and Treatment Satisfaction among Patients with Psoriasis and Psoriatic Arthritis and Patients with Psoriasis Only. <i>American Journal of Clinical Dermatology</i> , 2008, 9, 111-117.	6.7	45

#	ARTICLE	IF	CITATIONS
235	Targeting the IL-12/IL-23 cytokine family in the treatment of psoriatic disease. Expert Review of Dermatology, 2008, 3, 453-463.	0.3	2
236	Cardiovascular Disease and Risk Factors among Psoriasis Patients in Two US Healthcare Databases, 2001-2002. Dermatology, 2008, 217, 27-37.	2.1	155
237	Clobetasol propionate emollient formulation foam in the treatment of corticosteroid-responsive dermatoses. Expert Opinion on Pharmacotherapy, 2008, 9, 2001-2007.	1.8	10
238	Ketoconazole 2% foam for treatment of seborrheic dermatitis. Expert Review of Dermatology, 2008, 3, 15-21.	0.3	2
239	US Dermatology Residents' Satisfaction With Training and Mentoring. Archives of Dermatology, 2008, 144, 896-900.	1.4	42
240	Treatment Satisfaction and Health-related Quality of Life among Individuals with Psoriasis: National Psoriasis Foundation Survey Findings. Psoriasis Forum, 2008, 14a, 27-34.	0.1	1
241	Advances in the treatment of acne. Journal of reproductive medicine, The, 2008, 53, 742-52.	0.2	5
242	Innovative care, medical research, and the ethics of informed consent. Journal of the American Academy of Dermatology, 2007, 56, 330-332.	1.2	0
243	Reporting of ethical review of clinical research submitted to the Journal of the American Academy of Dermatology. Journal of the American Academy of Dermatology, 2007, 56, 279-284.	1.2	17
244	Practice patterns among osteopathic dermatologists in the United States. Journal of the American Academy of Dermatology, 2007, 56, 524-525.	1.2	7
245	Skin sun-acne tutorial evaluation among middle- and high-school students in central New Jersey. Journal of the American Academy of Dermatology, 2007, 56, 407-412.	1.2	12
246	Impact of adalimumab treatment on patient-reported outcomes: Results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. Journal of Dermatological Treatment, 2007, 18, 341-350.	2.2	91
247	Leadership Workforce in Academic Dermatology. Archives of Dermatology, 2007, 143, 948-9.	1.4	6
248	Psoriasis and psoriatic arthritis: separate or one and the same?. British Journal of Dermatology, 2007, 157, 850-860.	1.5	51
249	IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. Journal of Experimental Medicine, 2006, 203, 2577-2587.	8.5	610
250	Controlled nail trephination for subungual hematoma. American Journal of Emergency Medicine, 2006, 24, 875-877.	1.6	31
251	Striae gravidarum. Clinics in Dermatology, 2006, 24, 97-100.	1.6	65
252	Rising educational debt levels in recent dermatology trainees and effects on career choices. Journal of the American Academy of Dermatology, 2006, 54, 329-331.	1.2	12

#	ARTICLE	IF	CITATIONS
253	Determining the relative importance of patient motivations for nonadherence to topical corticosteroid therapy in psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2006, 55, 607-613.	1.2	189
254	Few Medicaid and uninsured patients are accessing dermatologists. <i>Journal of the American Academy of Dermatology</i> , 2006, 55, 1084-1088.	1.2	59
255	Accessibility to air travel correlates strongly with increasing melanoma incidence*. <i>Melanoma Research</i> , 2006, 16, 77-81.	1.2	44
256	Letter: Medical Versus Surgical Dermatology: How Much Training do Residents Receive?. <i>Dermatologic Surgery</i> , 2006, 32, 597-597.	0.8	6
257	How Low Should You Go: Novel Device for Nail Trephination. <i>Dermatologic Surgery</i> , 2006, 32, 828-833.	0.8	9
258	A Single-Blinded, Randomized, Controlled Clinical Trial Evaluating the Effect of Face Washing on Acne Vulgaris. <i>Pediatric Dermatology</i> , 2006, 23, 421-427.	0.9	63
259	Striae and Pelvic Relaxation: Two Disorders of Connective Tissue with a Strong Association. <i>Journal of Investigative Dermatology</i> , 2006, 126, 1745-1748.	0.7	35
260	Co-occurrence and comorbidities in patients with immune-mediated inflammatory disorders: an exploration using US healthcare claims data, 2001-2002. <i>Current Medical Research and Opinion</i> , 2006, 22, 989-1000.	1.9	95
261	An assessment of the cost-utility of therapy for psoriasis. <i>Therapeutics and Clinical Risk Management</i> , 2006, 2, 325-328.	2.0	10
262	The Psychosocial Burden of Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2005, 6, 383-392.	6.7	421
263	Clobetasol propionate foam in the treatment of psoriasis. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 1735-1740.	1.8	16
264	Rethinking the Psoriasis Area and Severity Index: the impact of area should be increased. <i>British Journal of Dermatology</i> , 2004, 151, 381-387.	1.5	83
265	Workforce Characteristics of Mohs Surgery Fellows. <i>Dermatologic Surgery</i> , 2004, 30, 136-138.	0.8	13
266	The dermatology workforce shortage. <i>Journal of the American Academy of Dermatology</i> , 2004, 50, 50-54.	1.2	136
267	Etanercept reduces pruritus in patients with moderate to severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2004, 50, P155.	1.2	0
268	The dermatology life quality index (DLQI) provides qualitatively different information from the pasi. <i>Journal of the American Academy of Dermatology</i> , 2004, 50, P156.	1.2	9
269	Gender and Parenting Significantly Affect Work Hours of Recent Dermatology Program Graduates. <i>Archives of Dermatology</i> , 2004, 140, 191-6.	1.4	36
270	Topical vitamins, minerals and botanical ingredients as modulators of environmental and chronological skin damage. <i>British Journal of Dermatology</i> , 2003, 149, 681-691.	1.5	109

#	ARTICLE	IF	CITATIONS
271	Dermatology: A unique case of specialty workforce economics. Journal of the American Academy of Dermatology, 2003, 48, 265-270.	1.2	35
272	The Response of Skin Disease to Stress. Archives of Dermatology, 2003, 139, 897-900.	1.4	187
273	Eruptive Xanthomas Associated With Olanzapine Use. Archives of Dermatology, 2003, 139, 1045-8.	1.4	25
274	Clinical and Immunologic Assessment of Patients With Psoriasis in a Randomized, Double-blind, Placebo-Controlled Trial Using Recombinant Human Interleukin 10. Archives of Dermatology, 2002, 138, 1341-6.	1.4	61
275	Diffuse morbilliform eruption after consumption of ginkgo biloba supplement. Journal of the American Academy of Dermatology, 2002, 46, 145-146.	1.2	23
276	Quantifying the harmful effect of psoriasis on health-related quality of life. Journal of the American Academy of Dermatology, 2002, 47, 512-518.	1.2	237
277	Cytarabine-induced acute generalized exanthematous pustulosis. Journal of the American Academy of Dermatology, 2002, 47, 633-635.	1.2	12
278	Magnetic resonance imaging detection of occult skin and subcutaneous abnormalities in juvenile dermatomyositis: Implications for diagnosis and therapy. Arthritis and Rheumatism, 2000, 43, 1866-1873.	6.7	132